Dr Fraser will continue in her role as Chief Scientific Officer while assuming the responsibilities of Interim CEO, ensuring continuity of leadership as the company advances its commercial and strategic objectives.
Dr Fraser has played a pivotal role in shaping Cytomos' scientific strategy and technology development, helping to position the company at the forefront of next-generation cell analytics. Her deep understanding of the business, technology and customer landscape uniquely equips her to lead the company through its next phase of growth.
"Dr Fraser has been instrumental in the development and success of Cytomos," said Dr Alan Raymond, Chair of the Board. "Her combination of scientific excellence, strategic vision and leadership makes her the ideal person to guide the company as Interim CEO. We are confident that Cytomos will continue to build momentum under her leadership."
Commenting on her appointment, Dr Fraser said: "I am honoured to take on the role of Interim CEO while continuing as Chief Scientific Officer. Cytomos has an exceptional team, transformative technology and a significant opportunity to support the rapidly growing cell and gene therapy sector. I look forward to continue working closely with our team, customers, partners and investors as we continue to execute our strategy and deliver value for all stakeholders."
The appointment reflects the commitment of Cytomos to maintaining strong leadership continuity while accelerating the development and commercialisation of its technology platform. The company remains focused on expanding customer engagements, advancing strategic partnerships and supporting the evolving needs of the cell and gene therapy industry.
29 September 2026
[gravityform id="1" title="false"]